申请人:THE WELLCOME FOUNDATION LIMITED
公开号:EP0174162A2
公开(公告)日:1986-03-12
The invention relates to compounds of formula (I), physiologically acceptable salts thereof, formulations containing
them, their preparation and their use in medicine.
In formula (I)
Q and Q'-Q8are independently selected hydrogen and C1-4 alkyl;
A is a group of formula -(CO)k-(N09)m-(CH2)n - where k and m are either both 0 or both 1, n is from 1 to 6, Q9 is selected from hydrogen and C1-4 alkyl and any of the -(CH2)n groups independently are optionally substituted by one or two C1-4 alkyl groups;
B is a C1-6 alkyl group;
E and Z are independently selected from carboxy derivatives thereof;
D is hydrogen or a C1-6 alkyl group which is optionally substituted by an amino group;
(X) is a benzene ring or a naphthyl or indolyl ring system any of which is optionally substituted in any position by one or more substituents independently selected from C1-4 (itself optionally substituted by one or more halogen atoms (C1-4 alkoxy, halo, nitro, amino, carboxy, C1-4 alkoxycarbonyl and hydroxy; and
-N Y is a pyrrolidinyl, oxazolidinyl or thiazolidinyl ring, or a ring system selected from indolinyl, quinolinyl and tetrahydroquinolinyl.
本发明涉及式 (I) 化合物、其生理上可接受的盐、含有它们的制剂、它们的制备以及它们在医药中的应用。
的制剂及其在医药中的应用。
在式 (I) 中
Q和Q'-Q8分别独立地选为氢和C1-4烷基;
A 是式-(CO)k-(N09)m-(CH2)n-的基团,其中 k 和 m 要么都是 0,要么都是 1,n 是 1 至 6,Q9 选自氢和 C1-4 烷基,且任何一个-(CH2)n 基团都独立地被一个或两个 C1-4 烷基任选取代;
B 是 C1-6 烷基;
E和Z各自选自其羧基衍生物;
D 是氢或任选被氨基取代的 C1-6 烷基;
(X) 是苯环或萘基或吲哚基环系,其中任一环系在任一位置任选被一个或多个取代基取代,这些取代基独立选自 C1-4(本身任选被一个或多个卤原子(C1-4 烷氧基、卤代、硝基、氨基、羧基、C1-4 烷氧基羰基和羟基)取代);以及
-N Y 是吡咯烷基、噁唑烷基或噻唑烷基环,或选自吲哚啉基、喹啉基和四氢喹啉基的环系。